AML Blood Test – A new method for the early detection and prognosis of acute myeloid leukemia
Diagnosing leukemia, especially acute myeloid leukemia (AML), is hindered due to the unspecific symptoms of the disease. Unfortunately misdiagnoses and mistreatments with antiviral or antibiotic medicine lead to a loss of precious time in fighting against this type of cancer.
Scientists from the University of Bonn tackled this challenge by developing a blood test. This test is based on one of the most advanced approaches of gene expression profiling: gene signatures. By adaptive learning and simulation the new blood test for acute myeloid leukemia (AML-BT) was generated. With an “RNA-fingerprint”, the analysis of the different indicator RNAs – showing a decreased or increased expression rate as indication for AML – can be conducted and used for a reliable diagnosis.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
